Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q61912424)
Watch
English
Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics
scientific article published in December 2011
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
title
Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
main subject
cystic fibrosis
1 reference
based on heuristic
inferred from title
author
Alan R. Smyth
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
author name string
Manfred Ballmann
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
David E Geller
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
publication date
1 December 2011
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
published in
Respiratory Medicine
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
volume
105 Suppl 2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
page(s)
S2-8
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
cites work
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bugs, biofilms, and resistance in cystic fibrosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Shifting patterns of inhaled antibiotic use in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nebulized antibiotic therapy: the evidence
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nebulizer delivery of tobramycin to the lower respiratory tract
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of nebulizer type and antibiotic concentration on device performance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Administration of aerosolized antibiotics in cystic fibrosis patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The clinical use of colistin in patients with cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Adherence with tobramycin inhaled solution and health care utilization
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970021-X
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0954-6111(11)70021-X
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
PubMed publication ID
22208546
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22208546
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208546%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
